Abstract
Hepatitis C virus (HCV) is the major etiological agent of human non-A and non-B hepatitis, affecting more than 170 million people worldwide. While the current standard of care for the treatment of HCV infection is ribavirin in combination with interferon-α (IFN-α), this therapeutic regimen presents several drawbacks, mainly related to important and serious side effects, to resistance issues, and to the lack of efficacy for the treatment of specific viral genotypes. In 2011, the FDA approved two HCV-targeted antivirals, namely boceprevir and telaprevir. These two drugs inhibit the protease activity of the viral enzyme NS3/4A, and in Phase III clinical trials proved to be effective in achieving sustained virological response rate up to 75%. However, problems associated with these therapeutic regimens still exist and need to be addressed. Intense research efforts in the field are aimed at discovering small-molecule inhibitors of HCV enzymes and proteins such as NS5B and NS5A and at developing NS3 protease inhibitors active against resistant viruses expressing mutated NS3 protease. The most recent advances for the rational drug design of such inhibitors are here reviewed.
Keywords: HCV, NS3/4A protease, NS3 helicase, NS5B polymerase, NS5A, rational drug design.
Current Pharmaceutical Design
Title:HCV-targeted Antivirals: Current Status and Future Challenges
Volume: 20 Issue: 21
Author(s): Sandra Gemma, Simone Brogi, Ettore Novellino, Giuseppe Campiani, Giovanni Maga, Margherita Brindisi and Stefania Butini
Affiliation:
Keywords: HCV, NS3/4A protease, NS3 helicase, NS5B polymerase, NS5A, rational drug design.
Abstract: Hepatitis C virus (HCV) is the major etiological agent of human non-A and non-B hepatitis, affecting more than 170 million people worldwide. While the current standard of care for the treatment of HCV infection is ribavirin in combination with interferon-α (IFN-α), this therapeutic regimen presents several drawbacks, mainly related to important and serious side effects, to resistance issues, and to the lack of efficacy for the treatment of specific viral genotypes. In 2011, the FDA approved two HCV-targeted antivirals, namely boceprevir and telaprevir. These two drugs inhibit the protease activity of the viral enzyme NS3/4A, and in Phase III clinical trials proved to be effective in achieving sustained virological response rate up to 75%. However, problems associated with these therapeutic regimens still exist and need to be addressed. Intense research efforts in the field are aimed at discovering small-molecule inhibitors of HCV enzymes and proteins such as NS5B and NS5A and at developing NS3 protease inhibitors active against resistant viruses expressing mutated NS3 protease. The most recent advances for the rational drug design of such inhibitors are here reviewed.
Export Options
About this article
Cite this article as:
Gemma Sandra, Brogi Simone, Novellino Ettore, Campiani Giuseppe, Maga Giovanni, Brindisi Margherita and Butini Stefania, HCV-targeted Antivirals: Current Status and Future Challenges, Current Pharmaceutical Design 2014; 20 (21) . https://dx.doi.org/10.2174/13816128113199990630
DOI https://dx.doi.org/10.2174/13816128113199990630 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preventive Antidepressant use in Patients with Hepatitis C Treated with Interferon-Alfa: a Systematic Review
Current Psychiatry Reviews Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology Matrix Metalloproteinases
Current Medicinal Chemistry The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Xiaoyao Pill Improves the Affective Dysregulation of Sleep-deprived Female Mice by Inhibiting Brain Injury and Regulating the Content of Monoamine Neurotransmitter
Current Pharmaceutical Biotechnology Apoptosis in Sepsis: Mechanisms, Clinical Impact and Potential Therapeutic Targets
Current Pharmaceutical Design A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry Investigation of the Metabolism of Rufinamide and Its Interaction with Valproate
Drug Metabolism Letters Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB
Anti-Cancer Agents in Medicinal Chemistry DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology Design, Synthesis, Molecular Docking Study and Anti-Hepatocellular Carcinoma Evaluation of New Bis-Triazolothiadiazines
Mini-Reviews in Medicinal Chemistry Sigma-2 Receptor Ligands: Neurobiological Effects
Current Medicinal Chemistry Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Phytomedicines are Efficient Complementary Therapies for the Treatment of Atopic Dermatitis: A Review of Mechanistic Insight and Recent Updates
Current Drug Targets Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents